Abbott reports fourth-quarter sales that miss analysts’ estimates.

Abbott's Medical Devices segment, especially CGM, continues to deliver robust double-digit growth, offsetting Nutrition ...

Abbott’s five-year data highlighted neuromodulation therapies’ role in reducing healthcare and patient burdens associated ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott’s neuromodulation systems can significantly reduce pain-related healthcare visits for people living with chronic pain, ...

By Christy Santhosh and Kamal Choudhury Jan 22 (Reuters) - Abbott forecast current-quarter profit below estimates after ...

Abbott Laboratories raised its dividend 7% and targets $5.80 EPS with 19.2x forward P/E and double-digit profit growth. See ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott Laboratories isn’t one to shy away from collaborations in the diabetes space. After all, the Abbott Park, IL-based company teamed up with rival Medtronic to develop a continuous glucose ...

Abbott's fourth quarter revenue missed expectations in its devices, diagnostics and nutrition segments, while staying in line for its established pharmaceutical business.